OPKO Health Receives 'Hold' Rating from Analysts

Analysts give the biotech company a mixed outlook on its stock performance

Apr. 11, 2026 at 8:29am

Got story updates? Submit your updates here. ›

A close-up, high-contrast image of intricate financial machinery and equipment, such as banking vaults or stock tickers, conveying the power and complexity of the financial industry as a conceptual metaphor for the mixed outlook on OPKO Health's prospects.Amid mixed analyst views, OPKO Health's financial machinery and infrastructure reflect the challenges and uncertainties facing the diversified healthcare company.Today in Miami

Shares of OPKO Health, Inc. (NASDAQ:OPK) have received an average 'Hold' recommendation from the six analysts currently covering the firm, according to Marketbeat. The analysts' ratings range from a 'Sell' to a 'Strong Buy', with the average 12-month price target set at $1.55.

Why it matters

OPKO Health is a diversified healthcare company focused on diagnostics, pharmaceuticals, and biologics development. The mixed analyst ratings and price targets reflect the company's challenges in its core business segments and the uncertainty around its future growth prospects.

The details

The analyst ratings for OPKO Health include one 'Sell' recommendation, three 'Hold' recommendations, one 'Buy' recommendation, and one 'Strong Buy' recommendation. The average 12-month price target of $1.55 suggests limited upside potential from the stock's current trading price around $1.16.

  • OPKO Health's latest quarterly earnings were reported on February 26, 2026.

The players

OPKO Health, Inc.

A diversified global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals, and biologics development.

Barrington Research

An investment research firm that covers OPKO Health and recently cut its price target on the stock.

Weiss Ratings

A financial research firm that recently downgraded OPKO Health's stock rating to a 'Sell'.

Wall Street Zen

A financial research firm that recently downgraded OPKO Health's stock rating to a 'Sell'.

Got photos? Submit your photos here. ›

What they’re saying

“Barrington Research cut their price target on shares of OPKO Health from $2.25 to $1.50 and maintained an 'Outperform' rating on the stock.”

— Barrington Research, Investment Research Firm

“Weiss Ratings reiterated a 'Sell (d-)' rating on shares of OPKO Health.”

— Weiss Ratings, Financial Research Firm

“Wall Street Zen cut shares of OPKO Health from a 'Hold' rating to a 'Sell' rating.”

— Wall Street Zen, Financial Research Firm

What’s next

Investors will be closely watching OPKO Health's upcoming earnings report and any updates on the company's strategic initiatives to address the challenges in its core business segments.

The takeaway

The mixed analyst ratings and price targets for OPKO Health reflect the ongoing uncertainties surrounding the company's growth prospects and the competitive landscape in the healthcare industry. Investors will need to carefully evaluate the company's long-term potential and execution capabilities to determine if the stock is worth considering.